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PHARMACOECONOMIC ANALYSIS OF ERLOTINIB COMPARED
WITH DOCETAXEL FORTHETREATMENT OF RELAPSED
NON-SMALL-CELL LUNG CANCER (NSCLC) INTURKEY
Batigun O,Yildirim E
Roche Müstahzarlari Sanayi AS, Istanbul, Maslak-Istanbul,Turkey
OBJECTIVES: To perform a cost-utility analysis of erlotinib
compared with docetaxel for treatment of advanced NSCLC
following the failure of prior chemotherapy from the perspective
of the Turkey health care system. METHODS: A cost-utility
analysis was performed using a transition model with three
health states (progression free, progression, death); primary end-
point of cost per quality-adjusted life year (QALY) gained. The
model compared the impact of erlotinib or docetaxel therapy
over a 2-year period (cycle length of 1 month) in patients with
stage IIIB/IV NSCLC who had failed at least one prior chemo-
therapy regimen. Clinical data from the BR.21 (erlotinib) and
TAX317 (docetaxel) phase III studies were used; for the purposes
of this analysis, it was conservatively assumed that overall sur-
vival was equivalent for the two interventions. The time spent in
each health state was adjusted for quality of life, including the
impact of adverse events (AEs). Costs included were: resource
utilisation for each health state and AE (including hospitalisa-
tion, physician visits, outpatient examinations, concomitant
medicines and required tests), drug acquisition and administra-
tion. RESULTS: The total discounted cost of erlotinib was
21,498 YTL (€11,943), compared with 21,667 YTL (€12,037)
for docetaxel. Erlotinib was associated with higher QALYs than
docetaxel (0.258 versus 0.206; incremental QALYs = 0.053),
mainly due to the lower incidence of AEs and the administra-
tion route (oral, versus intravenous for docetaxel). Erlotinib
was dominant versus docetaxel, with an incremental cost-
effectiveness ratio of –3227 YTL (–€1792) per QALY gained.
CONCLUSION: This is the ﬁrst pharmacoeconomic modelling
analysis performed for the setting of the Turkish health care
system. The results show that erlotinib is dominant versus doc-
etaxel for the treatment of relapsed advanced NSCLC, providing
higher QALYs at a lower cost. A major contributing factor to the
cost-savings observed with erlotinib is its favourable AE proﬁle,
particularly its lack of haematological toxicity.
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HEALTH SYSTEM CORRELATES OF RECEIPT OF RADIATION
AFTER BREAST CONSERVING SURGERY IN LOW-INCOME
MEDICAID-ENROLLED WOMEN
Anderson RT1, Balkrishnan R2
1Wake Forest University School of Medicine,Winston Salem, NC,
USA, 2The Ohio State University College of Pharmacy, Columbus,
OH, USA
OBJECTIVES: Breast-conserving surgery (BCS), followed by
radiation therapy (RT) is a safe and effective alternative to mas-
tectomy for most women with early stage breast cancer based on
evidence from prospective randomized trials, and has become the
preferred surgical option. Omission of RT after BCS, however, is
increasingly common and leads to poor outcomes. Few studies
examine patient and health system correlates to receipt of RT
after BCS, especially in a low income population. This study
described patient and health care systems correlates of receipt of
recommended care with BCS in North Carolina (NC) indicated
by receipt of adjuvant RT. METHODS: Subjects were women
diagnosed with primary breast cancer in 1998 and 1999 who
were classiﬁed as alive at least 12 months post-treatment with
BCS (N = 344). Medicaid claims were obtained to supplement
central cancer registry data on adjuvant RT; state county data
were obtained on health provider shortage regions. RESULTS:
Of 344 women in NC enrolled in Medicaid and treated with BCS
during the period of study, one third did not receive RT. The
following factors were associated with lack of receipt of RT after
BCS older age (65 > years), residence in a low population density
county, receiving BCS at a smaller-sized hospital, and living in a
county classiﬁed as whole-county specialist scarcity area (all
p < 0.05 in multivariate analyses). CONCLUSION: Some low
income women do not access RT following BCS, placing them at
risk for recurrence. We identiﬁed geographic isolation and scar-
city of health care as possible leverage points for interventions.
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USE,AND COSTS FOR PATIENTS WITH SCHIZOPHRENIA IN
FIVE EUROPEAN COUNTRIES
Leeuwenkamp O1, Knapp M2, McCrone P3
1NV Organon, Molenstraat, Oss,The Netherlands, 2London School of
Economics, London, UK, 3King’s College London, London, UK
OBJECTIVES: To allocate mental health resources effectively,
data are needed on resource use and costs associated with schizo-
phrenia. We analyzed the use and costs of clinical services in
patients with vs without negative symptoms of schizophrenia.
METHODS: Data were drawn from the cross-sectional Euro-
pean Psychiatric Services: Inputs Linked to Outcome Domains
and Needs (EPSILON) study, which was conducted in Amster-
dam, The Netherlands; Copenhagen, Denmark; London,
England; Santander, Spain; and Verona, Italy. Using Brief Psychi-
atric Rating Scale (BPRS) data, we produced three alternative
measures of negative symptoms: 1) a binary variable indicating
presence or absence of negative symptoms; 2) mean score for
individual BPRS negative symptom items; and 3) principal com-
ponents analysis of BPRS negative symptom items. We used
multiple regression models to analyze the impact of negative
symptoms on the use and costs of inpatient, outpatient, and
community-based services, controlling for age, sex, marital
status, employment status, race, education, psychiatric history,
and study center. RESULTS: Negative symptoms were present in
247 of 404 patients, with the lowest prevalence in Verona (49%)
and the highest in Amsterdam (79%). Compared with patients
with no negative symptoms, patients with negative symptoms
incurred higher mean costs for inpatient care (68% higher), day
care (116% higher), community services (48% higher), residen-
tial care (180% higher), and total costs (68% higher) but lower
costs for outpatient care (42% lower). After adjusting for socio-
demographic and clinical variables, negative symptoms were still
signiﬁcantly associated with higher inpatient and total costs. In
the analysis of service use, a signiﬁcant inverse relationship was
seen between the negative symptoms component score and use of
outpatient services. CONCLUSION: In this study of patients
with schizophrenia in ﬁve European countries, negative symp-
toms were most consistently correlated with higher inpatient and
total costs. Further investigation is merited.
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ASSESSINGTHE IMPACT OF A NATIONAL DRUG BENEFIT
PROGRAM ONTHE USE OF GENERIC DRUGS AND
DIFFERENTTHERAPEUTIC CLASSES
Zhang JX1,Yin W1, Sun SX2, Lee KY2, Meltzer DO1,Alexander GC1
1University of Chicago, Chicago, IL, USA, 2Walgreens Health Services,
Deerﬁeld, IL, USA
OBJECTIVES: To examine changes in the utilization of prescrip-
tion medicines from 16 therapeutic classes from 2005 to 2006
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